The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The impact of neoadjuvant chemotherapy (NAC) on conditional survival (CS) among patients with muscle-invasive bladder cancer (MIBC).
 
Nikhil Waingankar
No Relationships to Disclose
 
Rachel Jia
No Relationships to Disclose
 
Bart Ferket
No Relationships to Disclose
 
François Audenet
No Relationships to Disclose
 
Reza Mehrazin
No Relationships to Disclose
 
John Sfakianos
Consulting or Advisory Role - EMD Serono
Speakers' Bureau - Astellas Medivation; Astellas Medivation
 
Madhu Mazumdar
No Relationships to Disclose
 
Matt D. Galsky
Stock and Other Ownership Interests - Dual Therapeutics
Consulting or Advisory Role - Astellas Pharma; BioMotiv; Bristol-Myers Squibb; Dendreon; Genentech; GlaxoSmithKline; Janssen; Lilly; Merck
Research Funding - Bristol-Myers Squibb (Inst); Dendreon (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS. MOUNT SINAI SCHOOL OF MEDICINE July 2012 Application number: 20120322792
Travel, Accommodations, Expenses - Astellas Pharma; BioMotiv; Dendreon; Merck